Cargando…

Impact of a Population Genomic Screening Program on Health Behaviors Related to Familial Hypercholesterolemia Risk Reduction

Limited information is available regarding clinician and participant behaviors after disclosure of genomic risk variants for familial hypercholesterolemia (FH) from a population genomic screening program. METHODS: We conducted a retrospective cohort study of MyCode participants with an FH risk varia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Laney K., Chen, Nan, Hassen, Dina A., Betts, Megan N., Klinger, Tracey, Hartzel, Dustin N., Veenstra, David L., Spencer, Scott J., Snyder, Susan R., Peterson, Josh F., Schlieder, Victoria, Sturm, Amy C., Gidding, Samuel S., Williams, Marc S., Hao, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584046/ https://www.ncbi.nlm.nih.gov/pubmed/35862023 http://dx.doi.org/10.1161/CIRCGEN.121.003549

Ejemplares similares

Barriers, facilitators, and solutions to familial hypercholesterolemia treatment
por: Jones, Laney K., et al.
Publicado: (2020)

Patient experiences align with the familial hypercholesterolemia global call to action
por: Jones, Laney K., et al.
Publicado: (2022)

Collaborative Approach to Reach Everyone with Familial Hypercholesterolemia: CARE-FH Protocol
por: Jones, Laney K., et al.
Publicado: (2022)

Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program
por: Hao, Jing, et al.
Publicado: (2020)

Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis
por: Jones, Laney K., et al.
Publicado: (2021)

Acceptability, Appropriateness, and Feasibility of Automated Screening Approaches and Family Communication Methods for Identification of Familial Hypercholesterolemia: Stakeholder Engagement Results from the IMPACT-FH Study
por: Jones, Laney K., et al.
Publicado: (2021)

Facilitating family communication of familial hypercholesterolemia genetic risk: Assessing engagement with innovative chatbot technology from the IMPACT-FH study
por: Walters, Nicole L., et al.
Publicado: (2023)

Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis: Identification Methods, Patient Activation, and Cascade Testing for Familial Hypercholesterolemia
por: Campbell-Salome, Gemme, et al.
Publicado: (2021)

Maternal and Infant Health Care Costs Related to Preeclampsia
por: Hao, Jing, et al.
Publicado: (2019)

Yield of Familial Hypercholesterolemia Genetic and Phenotypic Diagnoses After Electronic Health Record and Genomic Data Screening
por: Gidding, Samuel S., et al.
Publicado: (2023)

Designing implementation strategies to improve identification, cascade testing, and management of families with familial hypercholesterolemia: An intervention mapping approach
por: Jones, Laney K., et al.
Publicado: (2023)

Hidden Burden of Electronic Health Record‐Identified Familial Hypercholesterolemia: Clinical Outcomes and Cost of Medical Care
por: Patel, Prashant, et al.
Publicado: (2019)

Applying implementation science to improve care for familial hypercholesterolemia
por: Jones, Laney K., et al.
Publicado: (2022)

Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia
por: Agarwala, Anandita, et al.
Publicado: (2021)

Economic Evaluation of Universal Lynch Syndrome Screening Protocols among Newly Diagnosed Patients with Colorectal Cancer
por: Hao, Jing, et al.
Publicado: (2021)

Optimizing communication strategies and designing a comprehensive program to facilitate cascade testing for familial hypercholesterolemia
por: Campbell-Salome, Gemme, et al.
Publicado: (2023)

Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States
por: Guzauskas, Gregory F., et al.
Publicado: (2020)

Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis
por: Jones, Laney K., et al.
Publicado: (2021)

Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor
por: Jarauta, Estíbaliz, et al.
Publicado: (2020)

Engaging Parents and Health Care Stakeholders to Inform Development of a Behavioral Intervention Technology to Promote Pediatric Behavioral Health: Mixed Methods Study
por: O'Dell, Sean M, et al.
Publicado: (2021)

Barriers and Facilitators to Genetic Testing for Familial Hypercholesterolemia in the United States: A Review
por: Hendricks-Sturrup, Rachele M., et al.
Publicado: (2019)

Analytical Validation of Familial Hypercholesterolemia Biomarkers in Dried Blood Spots
por: Held, Patrice K., et al.
Publicado: (2022)

Motivating cascade testing for familial hypercholesterolemia: applying the extended parallel process model for clinician communication
por: Campbell-Salome, Gemme, et al.
Publicado: (2022)

EPR-relations, von Neumann's standard forms and a proof concerning a conjecture of E. Scheibe
por: Schlieder, S
Publicado: (1994)

Mapping of familial hypercholesterolemia and dyslipidemias basic management infrastructure in Pakistan: a cross-sectional study
por: Sadiq, Fouzia, et al.
Publicado: (2023)

Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B
por: Williams, Katie B., et al.
Publicado: (2022)

Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia
por: Peterson, Amy L., et al.
Publicado: (2021)

Genetically confirmed familial hypercholesterolemia in outpatients with hypercholesterolemia
por: Wang, Xu, et al.
Publicado: (2018)

Translating guidelines into practice via implementation science: an update in lipidology
por: Jones, Laney K., et al.
Publicado: (2022)

Limited-Variant Screening vs Comprehensive Genetic Testing for Familial Hypercholesterolemia Diagnosis
por: Sturm, Amy C., et al.
Publicado: (2021)

Current causes of death in familial hypercholesterolemia
por: Marco-Benedí, Victoria, et al.
Publicado: (2022)

Familial Hypercholesterolemia
por: Baruah, Dibya Kumar
Publicado: (2021)

Putting Into Perspective the Hazards of Untreated Familial Hypercholesterolemia
por: Hopkins, Paul N.
Publicado: (2017)

The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia
por: Tandirerung, Fistra Janrio
Publicado: (2022)

Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohort
por: Lima, Isabella Ramos, et al.
Publicado: (2022)

Paradoxical reduction of plasma lipids and atherosclerosis in mice with adenine-induced chronic kidney disease and hypercholesterolemia
por: Padalkar, Mugdha V., et al.
Publicado: (2023)

Homozygous familial hypercholesterolemia
por: Parihar, Ravi Kumar, et al.
Publicado: (2012)

Homozygous Familial Hypercholesterolemia
por: Nohara, Atsushi, et al.
Publicado: (2021)

Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia
por: Sharifi, Mahtab, et al.
Publicado: (2017)

The burden of severe hypercholesterolemia and familial hypercholesterolemia in a population-based setting in the US
por: Saadatagah, Seyedmohammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r120ea3or68fivg8igvn7b9peg